1
|
Nolan D, Chin TR, Eamsureya M, Oppenheim S, Paley O, Alves C, Parks G. Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins. BIORESOUR BIOPROCESS 2024; 11:25. [PMID: 38647931 PMCID: PMC10991917 DOI: 10.1186/s40643-024-00738-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 02/01/2024] [Indexed: 04/25/2024] Open
Abstract
Monoclonal antibodies (mAbs) require a high level of purity for regulatory approval and safe administration. High-molecular weight (HMW) species are a common impurity associated with mAb therapies. Hydrophobic interaction chromatography (HIC) resins are often used to remove these HMW impurities. Determination of a suitable HIC resin can be a time and resource-intensive process. In this study, we modeled the chromatographic behavior of seven mAbs across 13 HIC resins using measurements of surface hydrophobicity, surface charge, and thermal stability for mAbs, and hydrophobicity and zeta-potential for HIC resins with high fit quality (adjusted R2 > 0.80). We identified zeta-potential as a novel key modeling parameter. When using these models to select a HIC resin for HMW clearance of a test mAb, we were able to achieve 60% HMW clearance and 89% recovery. These models can be used to expedite the downstream process development for mAbs in an industry setting.
Collapse
Affiliation(s)
- Douglas Nolan
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.
| | - Thomas R Chin
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - Mick Eamsureya
- Eurofins Lancaster Laboratories Professional Scientific Services, LLC, Lancaster, PA, 17601, USA
| | | | - Olga Paley
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - Christina Alves
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - George Parks
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| |
Collapse
|
2
|
Tang S, Tao J, Li Y. Challenges and solutions for the downstream purification of therapeutic proteins. Antib Ther 2024; 7:1-12. [PMID: 38235378 PMCID: PMC10791043 DOI: 10.1093/abt/tbad028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/27/2023] [Accepted: 11/15/2023] [Indexed: 01/19/2024] Open
Abstract
The innovation in recombinant protein technology has brought forth a host of challenges related to the purification of these therapeutic proteins. This article delves into the intricate landscape of developing purification processes for artificially designed therapeutic proteins. The key hurdles include controlling protein reduction, protein capture, ensuring stability, eliminating aggregates, removing host cell proteins and optimizing protein recovery. In this review, we outline the purification strategies in order to obtain products of high purity, highlighting the corresponding solutions to circumvent the unique challenges presented by recombinant therapeutic proteins, and exemplify the practical applications by case studies. Finally, a perspective towards future purification process development is provided.
Collapse
Affiliation(s)
- Shuo Tang
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| | - Jiaoli Tao
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| | - Ying Li
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| |
Collapse
|
3
|
Dilks AT, Gilchrist J, Lam Y, Nicholes N, Stanley B. Considerations for operational space definition and optimization of a no-salt flowthrough hydrophobic interaction chromatography purification step. Biotechnol Prog 2023; 39:e3351. [PMID: 37102582 DOI: 10.1002/btpr.3351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 02/17/2023] [Accepted: 03/29/2023] [Indexed: 04/28/2023]
Abstract
No-salt flowthrough hydrophobic interaction chromatography (HIC) has been shown to effectively remove process and product-related impurities from bioprocess streams. In this publication, a panel of six antibodies has been used to demonstrate operating principles for the application of no-salt flowthrough HIC in antibody purification processes. The results indicate that no-salt flowthrough HIC provides robust aggregate clearance across operating conditions including flow rate, and variations in resin ligand density. Additionally, HMW reduction has an optimal pH range relative to the isoelectric point of each molecule and high molecular weight (HMW) reduction can be improved by altering the total protein load and/or HMW concentration to drive binding of high molecular weight species to the resin.
Collapse
Affiliation(s)
| | | | - Yik Lam
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| | - Nathan Nicholes
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| | - Brad Stanley
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| |
Collapse
|
4
|
Chen SW, Hoi KM, Mahfut FB, Yang Y, Zhang W. Effective flow-through polishing strategies for knob-into-hole bispecific antibodies. BIORESOUR BIOPROCESS 2022; 9:98. [PMID: 38647877 PMCID: PMC10992779 DOI: 10.1186/s40643-022-00590-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 09/02/2022] [Indexed: 11/10/2022] Open
Abstract
Bispecific antibodies (bsAbs), though possessing great therapeutic potential, are extremely challenging to obtain at high purity within a limited number of scalable downstream processing steps. Complementary to Protein A chromatography, polishing strategies play a critical role at removing the remaining high molecular weight (HMW) and low molecular weight (LMW) species, as well as host cell proteins (HCP) in order to achieve a final product of high purity. Here, we demonstrate using two knob-into-hole (KiH) bsAb constructs that two flow-through polishing steps utilising Capto Butyl ImpRes and Capto adhere resins, performed after an optimal Protein A affinity chromatography step can further reduce the HCP by 17- to 35-fold as well as HMW and LMW species with respect to monomer by ~ 4-6% and ~ 1%, respectively, to meet therapeutical requirement at 30-60 mg/mL-resin (R) load. This complete flow-through polishing strategy, guided by Design of Experiments (DoE), eliminates undesirable aggregation problems associated with the higher aggregation propensity of scFv containing bsAbs that may occur in the bind and elute mode, offering an improved ease of overall process operation without additional elution buffer preparation and consumption, thus aligning well with process intensification efforts. Overall, we demonstrate that through the employment of (1) Protein A chromatography step and (2) flow-through polishing steps, a final product containing < 1% HMW species, < 1% LMW species and < 100 ppm HCP can be obtained with an overall process recovery of 56-87%.
Collapse
Affiliation(s)
- Serene W Chen
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Kong Meng Hoi
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Farouq Bin Mahfut
- Cell Line Development Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Yuansheng Yang
- Cell Line Development Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore
| | - Wei Zhang
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore, Singapore.
| |
Collapse
|
5
|
Hsu CH, Chen WL, Hsieh MF, Gu Y, C.-W. Wu K. Construction of magnetic Fe3O4@NH2-MIL-100(Fe)-C18 with excellent hydrophobicity for effective protein separation and purification. Sep Purif Technol 2022. [DOI: 10.1016/j.seppur.2022.121986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Kimerer LK, Pabst TM, Hunter AK, Carta G. Role of configurational flexibility on the adsorption kinetics of bivalent bispecific antibodies on porous cation exchange resins. J Chromatogr A 2021; 1655:462479. [PMID: 34461348 DOI: 10.1016/j.chroma.2021.462479] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 08/12/2021] [Accepted: 08/13/2021] [Indexed: 11/18/2022]
Abstract
The adsorption kinetics of a monoclonal antibody (mAb) used as a reference and of bivalent bispecific antibodies (BiSAb) on a macroporous cation exchanger is studied experimentally by examining the transient patterns of bound protein within the particles using confocal microscopy for a range of protein concentrations, buffer concentrations and pH, and temperatures. The mAb adsorption kinetics is controlled by pore diffusion and conforms to the classical shrinking core model. While the mAb adsorption rate increases with temperature, the ratio of effective and free solution diffusivity, De /D0, remains constant and has a value of 0.20. The BiSAb's structure is comprised of scFv domains that are genetically fused to a framework IgG through flexible peptide linkers which results in conformational flexibility leading to multiple binding forms with varying affinity for the adsorbent surface. As a result, adsorption of the BiSAbs shows complex patterns of total bound protein within the particles. These BiSAb adsorption patterns are influenced by buffer ionic strength, pH, and temperature in unique ways. Sharper intraparticle profiles are observed for conditions where the binding strength is greater (lower buffer concentration and/or pH) or when the protein is chemically crosslinked to restrict configurational flexibility. Temperature affects the BiSAb pore diffusivity as well as the interconversion kinetics. While the effects of temperature on BiSAb transport are also described by a constant De /D0 = 0.15, the temperature also affects the rate of interconversion between binding forms leading to faster equilibration at higher temperatures. A phenomenological model indicates that the interplay of pore diffusion and adsorption with the kinetically limited interconversion between binding forms is responsible for the experimental trends.
Collapse
Affiliation(s)
- Lucas K Kimerer
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA
| | - Timothy M Pabst
- Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Alan K Hunter
- Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Giorgio Carta
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA.
| |
Collapse
|
7
|
Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther 2021; 4:73-88. [PMID: 34056544 PMCID: PMC8155696 DOI: 10.1093/abt/tbab007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 04/06/2021] [Accepted: 04/29/2021] [Indexed: 12/12/2022] Open
Abstract
Bispecific antibodies (bsAbs) represent a highly promising class of biotherapeutic modality. The downstream processing of this class of antibodies is therefore of crucial importance in ensuring that these products can be obtained with high purity and yield. Due to the various fundamental structural similarities between bsAbs and monoclonal antibodies (mAbs), many of the current bsAb downstream purification methodologies are based on the established purification processes of mAbs, where affinity, charge, size, hydrophobicity and mixed-mode-based purification are frequently employed. Nevertheless, the downstream processing of bsAbs presents a unique set of challenges due to the presence of bsAb-specific byproducts, such as mispaired products, undesired fragments and higher levels of aggregates, that are otherwise absent or present in lower levels in mAb cell culture supernatants, thus often requiring the design of additional purification strategies in order to obtain products of high purity. Here, we outline the current major purification methods of bsAbs, highlighting the corresponding solutions that have been proposed to circumvent the unique challenges presented by this class of antibodies, including differential affinity chromatography, sequential affinity chromatography and the use of salt additives and pH gradients or multistep elutions in various modes of purification. Finally, a perspective towards future process development is offered.
Collapse
Affiliation(s)
- Serene W Chen
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore 138668, Singapore
| | - Wei Zhang
- Downstream Processing Group, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore 138668, Singapore
| |
Collapse
|
8
|
Kimerer LK, Niu B, Pabst TM, Zhai W, Hunter AK, Carta G. Chromatographic and adsorptive behavior of a bivalent bispecific antibody and associated fragments. J Chromatogr A 2021; 1648:462181. [PMID: 33989897 DOI: 10.1016/j.chroma.2021.462181] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Revised: 04/14/2021] [Accepted: 04/18/2021] [Indexed: 10/01/2022]
Abstract
The elution and adsorptive behavior of a bivalent bispecific antibody (BiSAb), comprising an IgG1 framework with a scFv domain genetically fused to each heavy chain C-terminus via flexible linkers, and of two associated fragments were studied on two cation exchange chromatography media - ProPac WCX-10, which is pellicular and suitable for analytical use, and Nuvia HR-S, which is macroporous and suitable for preparative and process scale uses. Both fragments were identified by MS as missing one of the two scFv domains and its flexible linker, but one of them also contains an additional C-terminal lysine. The separation of these fragments on both resins occurs as a result of differences in non-specific ligand-protein interactions that are modulated by the salt concentration. For the ProPac WCX-10 column, complex, multipeak elution behaviors are observed, since, as a result of the linker flexibility, both the intact molecule and the fragments appear to exist in multiple binding configurations with each scFv domains either collapsed onto the IgG framework or extended away from it. With a residence time of 2.5 min and at 21 °C, two peak elution is observed for the fragments which contain a single linked scFv and three peak elution for the intact molecule which contains two linked scFvs. This behavior is affected by residence time, temperature, and hold time. Increasing the residence time to 25 min or increasing temperature to 40°C results in elution of a single, merged peak for each of the protein species. For Nuvia HR-S, the broader peaks, obtained as a result of mass transfer limitations, tend to obscure the multipeak elution behavior. Nevertheless, even for this resin, the effects of configurational flexibility are still manifested at the single-particle scale and affect the evolution of the patterns of protein binding within individual resin particles as evident from confocal microscopy observations.
Collapse
Affiliation(s)
- Lucas K Kimerer
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA
| | - Ben Niu
- Analytical Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Timothy M Pabst
- Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Weiguo Zhai
- Analytical Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Alan K Hunter
- Purification Process Sciences, BioPharmaceuticals Development, AstraZeneca, Gaithersburg, MD, USA
| | - Giorgio Carta
- Department of Chemical Engineering, University of Virginia, Charlottesville, VA, USA.
| |
Collapse
|